tirzepatide and cancer 💊 Weight-loss drug shows cancer-fighting potential Researchers at the University of Michigan discovered that (Mounjaro, Zepbound), already FDA-approved for diabetes obesity, also shrinks breast tumors in obese mice. When Weight-loss drug Tirzepatide significantly slows

(5) glucose dysregulation suppresses the expression of antioxidant genes via the Nrf2/ARE pathway, weakening the antioxidant defense and DNA repair capacity of the p53 pathway (48, 49)

FDA submission is likely coming in 2026/2027 if the remaining readouts hold up Some other noteworthy drugs in the pipeline: Tirzepatide: The base drug is already approved for diabetes and obesity, but Lilly keeps expanding its label Kisunla (donanemab) for Alzheimer's Eloralintide: amylin receptor agonist heading to phase 3, at ADA it showed 20% weight loss on the amylin pathway alone MORF-057: bit of a wild card, after the $3.2 billion acquisition of Morphic

These medications markedly reduce appetite and food intake, with patients commonly reporting early satiety and decreased interest in eating

You have no confirmed deficiency but wish to support general health and energy levels